JP2018514550A - 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 - Google Patents

抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 Download PDF

Info

Publication number
JP2018514550A
JP2018514550A JP2017556651A JP2017556651A JP2018514550A JP 2018514550 A JP2018514550 A JP 2018514550A JP 2017556651 A JP2017556651 A JP 2017556651A JP 2017556651 A JP2017556651 A JP 2017556651A JP 2018514550 A JP2018514550 A JP 2018514550A
Authority
JP
Japan
Prior art keywords
antibody
ctla
antigen
binding portion
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514550A5 (enExample
Inventor
アービン・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56087499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018514550(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018514550A publication Critical patent/JP2018514550A/ja
Publication of JP2018514550A5 publication Critical patent/JP2018514550A5/ja
Priority to JP2021037367A priority Critical patent/JP2021105000A/ja
Priority to JP2024018579A priority patent/JP2024063023A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/5751—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017556651A 2015-04-28 2016-04-28 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 Pending JP2018514550A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021037367A JP2021105000A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
JP2024018579A JP2024063023A (ja) 2015-04-28 2024-02-09 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153973P 2015-04-28 2015-04-28
US62/153,973 2015-04-28
PCT/US2016/029877 WO2016176503A1 (en) 2015-04-28 2016-04-28 Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021037367A Division JP2021105000A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置

Publications (2)

Publication Number Publication Date
JP2018514550A true JP2018514550A (ja) 2018-06-07
JP2018514550A5 JP2018514550A5 (enExample) 2019-06-13

Family

ID=56087499

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017556651A Pending JP2018514550A (ja) 2015-04-28 2016-04-28 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
JP2021037367A Pending JP2021105000A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
JP2024018579A Pending JP2024063023A (ja) 2015-04-28 2024-02-09 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021037367A Pending JP2021105000A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
JP2024018579A Pending JP2024063023A (ja) 2015-04-28 2024-02-09 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置

Country Status (5)

Country Link
US (3) US10174113B2 (enExample)
EP (2) EP3288982A1 (enExample)
JP (3) JP2018514550A (enExample)
KR (2) KR20170138555A (enExample)
WO (1) WO2016176503A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213528A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
MA53243A (fr) * 2015-04-17 2021-06-23 Bristol Myers Squibb Co Compositions comprenant une combinaison de ipilimumab et nivolumab
EP3288982A1 (en) * 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
US11078278B2 (en) * 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
SI3334763T1 (sl) 2015-08-11 2025-01-31 WuXi Biologics Ireland Limited Nova protitelesa proti pd-1
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
EP4491237A3 (en) * 2016-10-28 2025-03-26 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
WO2018170329A1 (en) * 2017-03-17 2018-09-20 Nantomics, Llc LIQUID BIOPSY FOR cfRNA
EP3600426A4 (en) * 2017-03-31 2021-01-20 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY
BR112019023591A2 (pt) * 2017-05-09 2020-05-26 Tesaro, Inc. Terapias de combinação para tratar câncer
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
KR102522693B1 (ko) 2017-05-19 2023-04-17 우시 바이올로직스 (상하이) 컴퍼니 리미티드 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
MA50409A (fr) 2017-09-30 2020-08-26 Tesaro Inc Polythérapies pour le traitement du cancer
WO2019071123A1 (en) 2017-10-06 2019-04-11 Tesaro, Inc. POLYRHEERAPIES AND USES THEREOF
CA3083481A1 (en) * 2017-11-27 2019-05-31 Heat Biologics, Inc. Gp96-based cancer therapy
JP7490923B2 (ja) * 2018-02-02 2024-05-28 オンコシーフォー、インク． 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
KR20210141447A (ko) 2018-12-26 2021-11-23 실리오 디벨럽먼트, 인크. 항-ctla4 항체 및 이의 사용 방법
JP2022539019A (ja) * 2019-06-25 2022-09-07 シティ・オブ・ホープ Ｐｄｌ１陽性ｎｋ細胞がん処置
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
EP4482947A1 (en) 2022-02-24 2025-01-01 Amazentis SA Uses of urolithins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
HUE027525T2 (en) 2008-08-25 2016-11-28 Amplimmune Inc PD-1 Antagonist preparations and their use
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
BR112013026823A2 (pt) 2011-04-18 2016-12-27 Concentric Rockford Inc controle de velocidade para sistema de controle hidráulico
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
LT2734551T (lt) 2011-07-24 2018-04-10 Cure Tech Ltd. Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai
HUE035503T2 (en) 2012-10-02 2018-05-02 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
CA3078121A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3508502B1 (en) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3193921A4 (en) 2014-07-18 2018-04-25 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. VOL:19, NR:19, JPN5018002341, 1 October 2013 (2013-10-01), pages 5300 - 5309, ISSN: 0004381881 *
CLINICAL THERAPEUTICS, vol. VOL:37, NR:4, JPN5018002343, 1 April 2015 (2015-04-01), pages 764 - 782, ISSN: 0004381878 *
INTERNATIONAL IMMUNOLOGY, vol. VOL:27, NR:1, JPN5018002342, 16 October 2014 (2014-10-16), pages 39 - 46, ISSN: 0004381879 *
NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:369, NR:2, JPN5018002344, 11 July 2013 (2013-07-11), pages 122 - 133, ISSN: 0004381880 *

Also Published As

Publication number Publication date
US20160340428A1 (en) 2016-11-24
KR20240149980A (ko) 2024-10-15
US20220135685A1 (en) 2022-05-05
WO2016176503A1 (en) 2016-11-03
EP3288982A1 (en) 2018-03-07
JP2024063023A (ja) 2024-05-10
KR20170138555A (ko) 2017-12-15
US10174113B2 (en) 2019-01-08
EP3988571A1 (en) 2022-04-27
JP2021105000A (ja) 2021-07-26
US20190194328A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
US20220281974A1 (en) Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2024063023A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置
TWI821748B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
JP2020522691A (ja) Ｌａｇ−３陽性腫瘍の処置
JP2022188071A (ja) 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
WO2016191751A1 (en) Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US20230303700A1 (en) Cell localization signature and immunotherapy
KR20190015407A (ko) 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
RS64388B1 (sr) Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma
JP2022553851A (ja) 黒色腫の処置のためのｌａｇ－３アンタゴニスト
TWI912619B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201110

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210309

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20210330

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210330

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20210518

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20210608

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210608